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mucosal inflammation, accounts for over 250k physician visits annually with direct medical costs alone
exceeding 4 billion dollars annually. The disease, whose etiology is not well understood, can have severe
consequences such as colorectal cancer. First-line treatment for mild to moderate disease is topical 5-ASA
agents such as mesalamine. Patients refractory to this treatment are candidates for oral steroids, but these can
have severe side effects. Budesonide, a second-generation glucocorticoid already used topically for UC, has
less systemic effects, but needs an effective delivery mechanism as an oral form to treat areas unreachable via
topical solutions. Budesonide multi-matrix (MMX) was just approved January 2013 for treatment. Will it be
effective in inducing remission in patients with active, mild to moderate UC?
Methods: An exhaustive literature search using Medline-OVID, CINAHL, EBMR Multifile, and Web of
Science using the terms ulcerative colitis and budesonide was conducted. Lists from identified articles were
also investigated for further studies. Relevant articles were assessed for quality using the Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE).
Results: Two study articles were included in the review. CORE 1, a randomized, double-blind, double-
dummy study, determined the efficacy of budesonide MMX in inducing remission in ulcerative colitis patients
with active disease classified as mild to moderate. The other study was a randomized and double-blind
preliminary safety and efficacy study for budesonide MMX. Both studies demonstrated statistically significant
rates of remission induction with no increase in side effects
Conclusion: This systematic review indicates this drug as a viable option for patients with active, mild to
moderate UC who are refractory to first line therapies. A recommendation for the use of budesonide MMX as
an alternative can be given because of the evidence of efficacy, safety of the drug and the already-established
use of its two components.
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Abstract   
Background:  Ulcerative colitis (UC), a type of inflammatory bowel disease 
characterized by diffuse colonic mucosal inflammation, accounts for over 250k physician 
visits annually with direct medical costs alone exceeding 4 billion dollars annually.  The 
disease, whose etiology is not well understood, can have severe consequences such as 
colorectal cancer.  First-line treatment for mild to moderate disease is topical 5-ASA 
agents such as mesalamine.  Patients refractory to this treatment are candidates for oral 
steroids, but these can have severe side effects.  Budesonide, a second-generation 
glucocorticoid already used topically for UC, has less systemic effects, but needs an 
effective delivery mechanism as an oral form to treat areas unreachable via topical 
solutions.  Budesonide multi-matrix (MMX) was just approved January 2013 for 
treatment.  Will it be effective in inducing remission in patients with active, mild to 
moderate UC? 
 
Methods:  An exhaustive literature search using Medline-OVID, CINAHL, EBMR 
Multifile, and Web of Science using the terms ulcerative colitis and budesonide was 
conducted.  Lists from identified articles were also investigated for further studies.  
Relevant articles were assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE).  
 
Results:  Two study articles were included in the review. CORE 1, a randomized, 
double-blind, double-dummy study, determined the efficacy of budesonide MMX in 
inducing remission in ulcerative colitis patients with active disease classified as mild to 
moderate.  The other study was a randomized and double-blind preliminary safety and 
efficacy study for budesonide MMX.  Both studies demonstrated statistically significant 
rates of remission induction with no increase in side effects 
 
Conclusion:  This systematic review indicates this drug as a viable option for patients 
with active, mild to moderate UC who are refractory to first line therapies.  A 
recommendation for the use of budesonide MMX as an alternative can be given because 
of the evidence of efficacy, safety of the drug and the already-established use of its two 
components. 
 
Keywords:  Ulcerative colitis, budesonide, MMX  
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The Use of Budesonide MMX to Induce Remission in Active, Moderate to Mild 
Ulcerative Colitis:  A Systematic Review 
 
 
BACKGROUND 
 Ulcerative colitis (UC) is a chronic condition that is a type of inflammatory bowel 
disease (IBD) characterized by diffuse colonic mucosal inflammation. Bloody diarrhea is 
the hallmark symptom of UC.  Tenesmus and rectal urgency are also common symptoms.  
The clinical course involves flare-ups and remissions, which may occur spontaneously or 
as a response to treatment. 1  Serious consequences of UC can include toxic megacolon, 
massive hemorrhage, perforation, toxic colitis, and strictures.  Patients with long standing 
UC are at increased risk of developing epithelial dysplasia and carcinoma. 2  UC is 
classified by severity as mild, moderate, or severe based on factors such as the number of 
stools and signs of anemia. 3  
 The etiology is not clear and it is considered to be multi-factorial.  A consensus 
hypothesis is that in genetically predisposed individuals, both exogenous factors (eg, 
normal gut flora) and endogenous host factors (eg, intestinal epithelial cell barrier 
function, innate and adaptive immune function) interact to cause a chronic state of 
dysregulated mucosal immune function that is further modified by specific environmental 
factors (e.g., smoking). 2  Simply stated, the cause of IBD is currently considered an 
inappropriate immune response to these factors. 2  
 The disease accounts for over 250k physician visits annually, 30k 
hospitalizations, and loss of over a million workdays per year. 4  The direct medical costs 
exceed 4 billion dollars annually, comprising estimated hospital costs of over $960 
million 5, 6  and drug costs of $680 million. 6  Incidence of the disease is rising or just 
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beginning to stabilize in the entire world. As many as 1.4 million persons in the United 
States and 2.2 million persons in Europe suffer from IBD. 7  There is a clear need for 
effective pharmacotherapy.  
 The goal of treatment is induction and maintenance of remission, reduction in the 
need for the long-term use of corticosteroids, and minimization of cancer risk. 1  
Treatment is dictated by anatomic location of the disease and severity classification.  
Patients with mild to moderate UC can be treated with a topical 5-aminosalicylic acid  (5-
ASA) agent such as mesalamine, oral mesalamine, and topical steroids. 1  Topical 
mesalamine has traditionally been first line therapy, and is superior to topical 
corticosteroids. 3  Refractory cases are treated with oral prednisone or infliximab. 1  
However, these oral therapies do not have trivial side effect profiles, with prednisone 
causing cushingoid features (moon face, fat redistribution, striae), suppression of the 
hypothalamic-pituitary-adrenal axis, and many others. 1  Infusion reactions, abdominal 
pain, nausea, headache, diarrhea, and infections are the most common adverse events 
associated with infliximab reported in clinical trials. 8  
Budesonide, a second generation glucocorticoid, has less systemic effects than 
typical steroids such as prednisone. 9  It has been used for the treatment for UC for more 
than 10 years, but used as a topical solution.  Because of its extensive first-pass 
metabolism, oral budesonide would be ineffective as the drug would be unavailable to the 
colon after going through the stomach.  And a topical formula would only be effective as 
far as an enema could deliver the drug.  Topical steroids and 5-ASA agents have been in 
use for the treatment of proctitis (inflammation of the rectum) for many years. 9  A 
coating, called MMX (multi-matrix), which allows a drug to survive gastric acidity and 
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be available in the colon, was added to oral mesalamine and approved in 2007 for use in 
UC. 1  This, along with topical mesalamine, became an effective treatment combination.  
But this did not help patients refractory to mesalamine.  A similarly effective delivery 
mechanism for budesonide was needed.  A study for oral budesonide MMX was 
conducted in 2005 on healthy males, demonstrating that this combination is suitable for 
targeted colonic drug delivery. 10  The next step was to determine efficacy in UC patients.  
A study took place in 2011 demonstrating efficacy, and, in January of 2013, budesonide 
MMX for UC was approved by the FDA under the trade name Uceris®. 9  Does the use of 
budesonide MMX induce remission in active, moderate to mild UC? 
METHODS 
An exhaustive literature search using Medline-OVID, CINAHL, EBMR Multifile, 
and the Web of Science using the terms ulcerative colitis and budesonide was conducted.  
Lists from identified articles were also investigated for further studies.  The search was 
narrowed by using only English language articles, and for studies that involved human 
subjects.  Further narrowing was employed; included were full-text articles with primary 
data, randomized control trials with the non-control patients having ulcerative colitis, 
trials with oral formulas only, trials after 2009, and trials whose endpoint was induction 
of remission. Also, a search was conducted on the National Institute of Health clinical 
trials site using the term budesonide MMX to reveal all of the trials associated with the 
therapy.  Relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE). 11   
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RESULTS 
The initial search revealed 152 articles.  After duplicates were removed, and the 
inclusion and exclusion criteria applied, two study articles remained; 9, 12 see Figure I for 
details on the search.  Both studies are randomized control trials comparing budesonide 
MMX against placebo.  Both were sponsored by Santarus, a biopharmaceutical company 
that produces Uceris®, which is the trade name for budesonide MMX. 13  The study 
period of comparing budesonide MMX to placebo was 8 weeks in the CORE 1 study, 9  
but only 4 weeks in the safety and efficacy study. 12  Also, in the safety and efficacy 
study, the diagnosis for the patients was specific to left-sided ulcerative colitis, 12  
whereas in the CORE 1 study, it was not as specific. 9  See Table I for study details and 
Table II for a summary of the findings. 
CORE 1 Study 
This was a randomized, double-blind, double-dummy, placebo-controlled, 8-week 
trial 9  to determine the efficacy of budesonide MMX in inducing remission in ulcerative 
colitis patients with active disease classified as mild to moderate.  It was a multi-center 
study conducted at 108 centers in North America and India between August 2008 and 
May 2010. 9  This was the phase three trial for the drug.  The trial had 509 patients who 
were up to 75 years old with active, mild-to-moderate ulcerative colitis for at least 6 
months and with an ulcerative colitis disease activity index (UCDAI) score of 4-10 
points.  The UCDAI is a composite score of four items (stool frequency, rectal bleeding, 
mucosal appearance, and physician’s rating of disease activity).  Concurrent therapy for 
UC was not permitted during the study.  Patients receiving oral mesalamine or other oral 
5-aminosalicyclic medications at the screening visit were required to wash out of their 
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medication at least 2 days before randomization.  Exclusion criteria included diagnosis of 
severe UC (UCDAI >10 points); evidence or history of toxic megacolon; disease limited 
to the rectum (proctitis extending from the anal verge up to 15 cm); presence of 
infectious colitis; presence of severe anemia, leukopenia, or granulocytopenia; verified, 
presumed, or expected pregnancy or ongoing lactation; presence of cirrhosis or evident 
hepatic or renal disease or insufficiency; presence of severe diseases in other organs and 
systems; local or systemic complications or other pathological states requiring therapy 
with corticosteroids and/or immunosuppressive agents; type 1 diabetes; glaucoma; or 
known infection with hepatitis B or C or with human immunodeficiency virus. 9   
 The primary endpoint was combined clinical and endoscopic remission at week 
eight.  Secondary endpoints were clinical improvement, endoscopic improvement, 
histologic healing and symptom resolution.  Patients were randomized to one of four 
treatments at a 1:1:1:1 ratio using a block size of 4. As each new patient was randomized 
via the interactive voice response system, he or she was given the next available 
randomization number that was associated with a study drug. Patients were followed up 
through week 10. A follow-up safety visit was to be conducted two weeks after the final 
visit (week 8 or early withdrawal). The interactive voice response system was used to 
centrally randomize patients to study drug. A double-dummy procedure was used to 
maintain blinding, with patients in each treatment group receiving their blinded study 
drug 3 times daily.  The four treatment groups in the 8-week trial were:  9mg budesonide 
MMX each day, 6mg budesonide MMX each day, 1.2 grams of mesalamine each day, 
and placebo.  The main study drug and focus of this systematic review was 9mg 
budesonide.  The 6-mg dose strength was included as an additional treatment arm, at the 
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request of regulatory authorities, to establish the lowest effective dose for budesonide 
MMX in inducing remission in active mild to moderate UC.  A non-powered reference 
arm using Asacol (mesalamine) 2.4 g was also included as active control and internal 
reference.  The 9mg budesonide MMX group had 123 patients and the placebo group had 
121 patients. 9  
 Budesonide MMX significantly increased the rate of combined endoscopic and 
clinical remission (relative risk (RR)=2.40, number needed to treat (NNT)=10), clinical 
improvement (RR=1.32, NNT=13), endoscopic improvement (RR=1.20, NNT=13), and 
symptom resolution (RR=1.65, NNT=9).  However, there was not a significant increase 
in histologic healing, in fact, treatment favored placebo.  (RR=0.62, number needed to 
harm (NNH)=40). 9  See Table III for study end points. 
 Treatment with budesonide MMX was generally well tolerated with an overall 
safety profile similar to placebo.  The percentage of patients with severe AEs was highest 
in the placebo group.  There was no evidence of any increase in glucocorticoid effects in 
the budesonide MMX groups when compared to the placebo group.  There was a 
decrease in mean morning plasma cortisol levels at weeks two four for the budesonide 
MMX groups, but the levels gradually increased toward baseline values by the final visit. 
9
  See Figure 2 for details of the glucocorticoid effects across the treatment groups. 
Preliminary Safety and Efficacy Study 
This was a European pilot multicenter efficacy study 12  conducted in 2009 that 
was a randomized, double-blind, placebo-controlled 4-week trial to determine if 
budesonide 9mg MMX could induce clinical remission and improvement in patients with 
active moderate left-sided ulcerative colitis, while other ulcerative colitis therapies were 
 - 11 - 
kept stable such as 5-ASA.  An additional 4-week period of open-label treatment was 
conducted in which all of the study participants received active treatment. 12   
After screening 56 patients, 36 patients were enrolled in the study.  The original 
intent was to have 40 patients, but the trial was interrupted before reaching the planned 
sample of 40 subjects.  Also, not all 36 patients completed four weeks in the trial. 
Because of worsening disease, after two weeks, five patients switched from placebo to 
open-label active treatment. 12   
Patients were males and females with a diagnosis of active, left-sided ulcerative 
colitis (up to the splenic flexure) with a clinical activity index (CAI) < 14, which would 
exclude severe disease. 12  CAI is a validated instrument to reflect the severity of 
ulcerative colitis, which was defined by a clinical activity grading system.  The index is 
composed of the number of weekly stools, weekly average of blood in stool, abdominal 
pain/cramps, among others. 14  These patients were on stable treatment with oral 5-ASA 
at a dose between 0 and 3 grams a day for at least two months before the study. Exclusion 
criteria: distal proctitis (<15 cm above the anal verge from the pectineal line), severe left-
sided ulcerative colitis (CAI N14), extensive colitis proximal to the splenic flexure, and 
infections as a cause of relapse. Also, patients, who had been using oral or topical 
steroids in the last 4 weeks, could not participate.  The use of immunosuppressive 
medication was disallowed with the exception of 6-mercaptopurine and azathioprine. 
Other reasons for exclusion were prior treatment with anti-TNF agents, use of NSAIDs or 
drugs affecting the colonic motility including antidiarrheal and drugs altering the pH of 
the intestinal content. Pregnancy and severe concomitant diseases also represented 
exclusion criteria. 12   
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The primary endpoint was achieving a relevant clinical improvement that was 
defined as either remission (which means a CAI <=4), or a reduction of CAI by 50% 
from the baseline value.  Further objectives of the trial were the evaluation of reduction in 
clinical symptoms after eight weeks of treatment, evaluation of endoscopic and 
histological changes, and c-reactive protein (CRP) level after four and eight weeks of 
treatment. 12   
The study population average age was 44.5±12.6, body weight averaged 72.7±15 
kg, and height averaged 171.7±9.5 cm. The placebo group was 9 males and 9 females, 
while the treatment group was 12 males and 6 females.  The mean duration of ulcerative 
colitis from diagnosis to the start of the study varied from 0 to 35 years in both groups; in 
the budesonide group it was nine years and in the placebo group it was 10 years. 12   
Budesonide MMX significantly increased the rate of achieving clinical 
improvement (meaning either remission, defined as a CAI ≤ 4 or a CAI reduction by at 
least 50% of the baseline value) after four weeks of treatment (RR=1.42, NNT=7). 
Reduction in endoscopic index from baseline for budesonide MMX was 6.44 (±3.27) 
from 9.06 (±1.79) and for placebo it was 6.33 (±2.64) from 8.53 (±2.10).  Reduction in 
histologic index from baseline for budesonide MMX was 1.69 (±0.70) from 1.82 (±0.53). 
 Histologic index actually increased for placebo to 1.8 (±0.77) from 1.67 (±1.05).  Figure 
III shows CRP changes from baseline levels.  After four weeks the budesonide MMX 
group CRP level fell from 1.09 (±1.23) mg/dL (CI 0-4.80) to 0.47 (±0.5) mg/dL (CI 0-
1.66); a smaller decrease was measured for placebo after four weeks but the actual 
number was not given. 12  
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DISCUSSION 
 UC is a disease that severely impacts one’s lifestyle, can have deadly 
consequences, and is a significant worldwide problem.  There is an array of treatment 
options, of which topical mesalamine is first line.  Oral mesalamine was developed for 
disease unreachable by topical therapy, and special coatings were developed to allow the 
oral drug to remain intact long enough to reach all areas of the colon.  For patients 
refractory to mesalamine, corticosteroids and infliximab have been used but with 
significant side effects.  Budesonide, a steroid that undergoes significant first-pass 
metabolism, was used for UC patients unresponsive to mesalamine, but similarly to first 
generations of oral mesalamine, getting the drug to the colon intact was a challenge.  The 
MMX coating, first used successfully in oral mesalamine, was combined with budesonide 
and approved by the FDA in January 2013. 9     
The goal of this review was to determine the efficacy and safety of budesonide 
MMX by critically appraising applicable drug studies and making a recommendation for 
clinical practicality if the evidence supports it.  Two studies were analyzed and both show 
statistically significant improvement in both patient-important outcomes and surrogate 
outcomes, establishing Budesonide MMX as an alternative therapy to mesalamine for UC 
patients. However, both studies have their limitations and potential for bias.  
 The CORE 1 study 9 is a study of moderate quality that shows statistically 
significant improvement vs. placebo in remission induction, clinical improvement, 
endoscopic improvement, and symptom resolution for the budesonide treatment group.  
The study does not have any major limitations in methodology, it was a randomized, 
double-blind, and double-dummy study, there were no patients lost to follow-up, and 
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there were no increases in medicine adverse effects.  There were no serious 
inconsistencies in the study as the study and placebo groups were mostly prognostically 
balanced except for gender.  The percentage of male/female patients in the budesonide 
MMX and placebo groups were 62.6/46 and 56.2/53 respectively.  However, this isn’t 
significant, as gender has not been proven to affect prognosis in UC.   The study does not 
have serious indirectness; the primary outcome is not a surrogate outcome and it is the 
outcome of interest in the study.  However, there is a high probability of a risk of 
publication bias, as Santarus, the company that produces Uceris®, funded the study.  This 
downgraded the quality of the study from high to moderate. 
 The preliminary safety and efficacy study 12  is a study of low quality that shows 
statistically significant improvement vs. placebo in relevant clinical improvement, a 
reduction in clinical symptoms, improvement in endoscopic and histological changes, as 
well as a reduction in CRP.  The study does not have any major limitations in 
methodology.  It was a randomized, double-blind study and there were no patients lost to 
follow-up.  Also, there were no increases in medicine side effects.  There were no serious 
inconsistencies; the study and placebo groups were mostly prognostically balanced 
except for gender; the number of male/female patients in the budesonide MMX and 
placebo groups were 12/6 and 9/9, respectively.  Again, this doesn’t impact prognosis.  
The study has serious imprecision as the sample size is small. There is a high probability 
of a risk of publication bias; similarly to CORE 1, Santarus funded this study.  These 
items caused the quality of the study to be graded as low.  
 For researchers, there are two other areas of research that need to be investigated: 
 A comparison of efficacy of budesonide MMX to mesalamine MMX in remission 
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induction and an evaluation of the efficacy of budesonide MMX in maintaining 
remission.  The remission maintenance study was completed in 2012. 15  No papers have 
been published detailing the results, but the study involves patients from the CORE 1 
study who remained in remission and were treated and followed for 12 months.  15  
CONCLUSION 
 Budesonide MMX is a drug newly approved in January of 2013 for use in UC that 
is a combination of two established pharmaceuticals.  This systematic review indicates 
this drug as a viable option it for inducing remission in UC patients who are refractory to 
treatments that are established and considered first-line.  The evidence shows statistically 
significant improvement in outcomes. While the studies have their limitations based on 
the GRADE criteria, given the low incidence of side effects and the high incidence and 
devastating impact of this disease, a clinician would need to consider this as an 
alternative therapy for UC patients who are refractory to other treatments.  A 
recommendation for the use of budesonide MMX can be given. 
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Table I. Characteristics of Reviewed Studies 
Table 1 GRADE evidence profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment  
 Downgrade Criteria 
Quality Importance 
Study Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Combined clinical and endoscopic remission (primary endpoint)   
Core 1 9  RCT 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Industry funded, bias likely -1 Moderate Important 
Relevant clinical improvement (remission as defined by CAI <= 4 or a CAI reduction >=50% of baseline); (primary endpoint)   
Prelim safety 
and efficacy 12  
RCT 
No serious 
limitations 
No serious 
indirectness 
Information size 
small  
-1 
No serious inconsistencies Industry funded, bias likely -1 Low Important 
CAI Improvement (secondary endpoint   
Prelim safety 
and efficacy 12  
RCT 
No serious 
limitations 
No serious 
indirectness 
Information size 
small -1 
Gender differences between 
treatment and placebo 
group -1 
Industry funded, bias likely -1 Very low Important 
Clinical improvement (secondary endpoint)   
Core 1 9  RCT 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Industry funded, bias likely -1 Moderate Important 
Endoscopic improvement (secondary endpoint)   
Core 1 9  RCT 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Industry funded, bias likely -1 Moderate Important 
Histologic Healing (secondary endpoint)   
Core 1 9  RCT 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Industry funded, bias likely -1 Moderate Important 
Symptom Resolution (secondary endpoint)   
Core 1 9  RCT 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Industry funded, bias likely -1 Moderate Important 
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Table II. Summary of Findings 
 
 
 
 
Table III. CORE 1 Study Primary and Secondary End Points 9  
 Placebo (n=121) Budesonide MMX 9mg 
(n=123) 
Budesonide MMX 6mg 
(n=121) 
Asacol 2.4g (n=124)Com 
Combined clinical and 
endoscopic remission, n (%) 
9 (7.4) 22 (17.9) 16 (13.2) 15 (12.1) 
95% CI 2.8 to 12.1 11.1 to 24.7 7.2 to 19.3 6.4 to 17.8 
Clinical improvement 30 (24.8) 41 (33.3) 37 (30.6) 42 (33.9) 
Endoscopic improvement 40 (33.1) 51 (41.5) 43 (35.5) 41 (33.1) 
Histologic healing 8 (6.6) 5 (4.1) 9 (7.4) 14 (11.3) 
Symptom resolution 20 (16.5) 35 (28.5) 35 (28.9) 31 (25.0) 
 
 
 
 
 
 
 
 Number of Patients Outcomes 
Study 
Treatment 
(total) 
Placebo or 
no 
treatment 
(total) 
Combined 
clinical and 
endoscopic 
remission 
Relevant clinical improvement 
(remission as defined by CAI <= 4 
or a CAI reduction >=50% of 
baseline) 
Clinical 
improvement 
Endoscopic 
improvement 
Histologic 
Healing 
Symptom 
Resolution 
CORE 1 123 121 
RR=2.40, 
NNT=10 
 
RR=1.3, 
NNT=13 
RR=1.20, 
NNT=13 
RR=0.57 
NNT=-3 
RR=1.65, NNT=9 
Preliminary safety and efficacy 17 15  RR=1.4, NNT=7     
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Figure I. Search Methodology 
PRISMA 2009 Flow Diagram 
 
  
Records identified through 
database searches 
(n =  152 ) 
Additional records identified 
through other sources 
(n =  9 ) 
Records after duplicates, non-human, and 
non-English removed 
(n =  103) 
Records screened 
(n =  30 ) 
Records excluded 
(n =  73 ) 
Full-text articles assessed 
for eligibility 
(n =   6) 
Full-text articles excluded, 
with reasons 
(n =   24) 
Studies included in 
systematic review 
(n =  2 ) 
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Figure II. CORE 1 Study Glucocorticoid Effects and Plasma Cortisol 
Levels 
 
Reprinted with permission from Gastroenterology. 9  
Figure III. Safety and Efficacy Study Mean CRP Levels 
 
 
Reprinted with permission from Journal of Crohn's & colitis. 12  
